| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof | US14303641 | 2014-06-13 | US09233915B2 | 2016-01-12 | Samuel Fortin |
| There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer. | ||||||
| 82 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | US14707472 | 2015-05-08 | US20150266814A1 | 2015-09-24 | Xianqi Kong; Nigel Levens; Abderrahim Bouzide; Stephane Ciblat; Richard Frenette; Johanne Renaud |
| The invention relates to methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 1,3PDS, either in vitro or in vivo. The invention also relates to sulfonate ester prodrugs of 1,3PDS as well as Gemini dimmers and oligomers of 1,3PDS for the prevention or treatment of associated diseases and conditions. | ||||||
| 83 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS | US14409352 | 2013-06-17 | US20150182534A1 | 2015-07-02 | Rolf W. Pfirrmann |
| New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. | ||||||
| 84 | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof | US12535048 | 2009-08-04 | US08329747B2 | 2012-12-11 | Samuel Fortin |
| There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer. | ||||||
| 85 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | US13388405 | 2010-08-03 | US20120130089A1 | 2012-05-24 | Ayako Kuramoto; Kuniaki Okamoto; Tsutomu Watahiki; Motoshige Sumino |
| The present invention is directed to provide an efficient production method which is capable of not only obtaining a cyclic sulfonic acid ester (sultone) at low cost and in high yield, but also the sulfonic acid ester (sultone) stably even in a commercial scale. The present invention relates to a method for producing hydroxysultone comprising a first step where a diol having a specified structure and a thionyl halide are reacted to obtain a cyclic sulfite having a specified structure, and a second step where the cyclic sulfite is reacted with water or/and alcohol; a method for producing an unsaturated sultone having a specified structure comprising a third step where a hydroxylsultone having a specified structure is reacted with an acid halide or an acid anhydride to obtain an intermediate, subsequently the intermediate is treated with a base; as well as a cyclic sulfite having a specified structure. | ||||||
| 86 | METHODS FOR SYNTHESIZING KOTALANOL AND STEREOISOMERS AND ANALOGUES THEREOF, AND NOVEL COMPOUNDS PRODUCED THEREBY | US12934898 | 2009-03-25 | US20110268822A1 | 2011-11-03 | Brian Mario Pinto; Jayakanthan Kumarasamy; Ravindranath Nasi; Sankar Mohan |
| Compounds having the general formula (I): wherein X is S, Se or NH, and stereoisomers thereof, and de-O-sulfonated analogues of all of the foregoing, but excluding naturally occurring kotalanol and de-O-sulfonated kotalanol, and methods for synthesizing same. The compounds are useful as glycosidase inhibitors, and may be used in the treatment of diabetes. The synthetic compounds may also be used as standards in the calibration or grading of natural or herbal remedies produced from natural sources of glycosidase inhibitors such as kotalanol. | ||||||
| 87 | ORGANIC CATALYST WITH ENHANCED SOLUBILITY | US13168175 | 2011-06-24 | US20110253931A1 | 2011-10-20 | Gregory Scot MIRACLE; George Douglas Hiler, II; Susumu Murata; Rebecca Massie Grey |
| This invention relates to organic catalysts comprising iminium or oxaziridinium moieties, cleaning compositions comprising such catalysts; and processes for making and using such catalysts and cleaning products. | ||||||
| 88 | Organic catalyst with enhanced solubility | US12366055 | 2009-02-05 | US07994109B2 | 2011-08-09 | Gregory Scot Miracle; George Douglas Hiler, II; Susumu Murata; Rebecca Massie Grey |
| This invention relates to organic catalysts comprising iminium or oxaziridinium moieties, cleaning compositions comprising such catalysts; and processes for making and using such catalysts and cleaning products. | ||||||
| 89 | Chiral binaphthyl sulfates for use as liquid crystal materials | US12296598 | 2007-03-16 | US07943061B2 | 2011-05-17 | Louise Diane Farrand; Patricia Eileen Saxton |
| The invention relates to chiral compounds, methods of their preparation, and to their use in optical, electrooptical, electronic, semiconducting or luminescent components or devices, and in decorative, security, cosmetic or diagnostic applications. | ||||||
| 90 | Structural analogs of corosolic acid having anti-diabetic and anti-inflammatory properties | US10543387 | 2004-07-08 | US07893263B2 | 2011-02-22 | Ganga Raju Gokaraju; Rama Raju Gokaraju; Venkata Subbaraju Gottumukkala; Trimurtulu Golakoti; Venkateswarlu Somepalli; Venkateswara Rao Chirravuri |
| This invention relates to novel corosolic acid analogs of the formula I, wherein R1, R2, R3, R4 and R5 are described herein. These compounds exhibit good hypoglycemic and 5-lipoxygenase inhibitory activities. They also inhibit tumour growth. Pharmaceutical compositions containing known adjutants and the title compounds are also within the scope of this invention. | ||||||
| 91 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | US12535048 | 2009-08-04 | US20100160261A1 | 2010-06-24 | Samuel FORTIN |
| There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer. | ||||||
| 92 | CHIRAL BINAPHTHYL SULFATES FOR USE AS LIQUID CRYSTAL MATERIALS | US12296598 | 2007-03-16 | US20100019199A1 | 2010-01-28 | Louise Diane Farrand; Patricia Eileen Saxton |
| The invention relates to chiral compounds, methods of their preparation, and to their use in optical, electrooptical, electronic, semiconducting or luminescent components or devices, and in decorative, security, cosmetic or diagnostic applications. | ||||||
| 93 | ORGANIC CATALYST WITH ENHANCED SOLUBILITY | US12366055 | 2009-02-05 | US20090143272A1 | 2009-06-04 | Gregory Scot Miracle; George Douglas Hiler, II; Susumu Murata; Rebecca Massie Grey |
| This invention relates to organic catalysts comprising iminium or oxaziridinium moieties, cleaning compositions comprising such catalysts; and processes for making and using such catalysts and cleaning products. | ||||||
| 94 | Process for the stereoselective preparation of insecticide 6,7,8,9,10-10-hexahalo-1, 5, 5a, 6, 9, 9a-hexadro-6, 9-methano-2, 4, 3-benzodioxathiepin-3-oxide | US10474029 | 2003-10-10 | US20040092751A1 | 2004-05-13 | Ashwin Champraj Shroff; Abhijit Premvallabh Purohit; Sanjay Dhirajlal Vadoraria |
| A process for the stereoselective preparation of insecticide 6,7,8,9,10,10-hexahalo-1,5,5a,6,9,9a-hexahydro-6,9-methano-2,4,3-benzodioxathiepin-3-oxide of the general formula 1: 1 wherein X is a halogen such as fluorine, chlorine or bromine. The process comprises reacting 1,4,5,6,7,7-hexahalo-5-norbornene-2,3-dimethanol of the general formula IV: 2 wherein X is as defined above, with a cyclic sulfite ring forming reagent optionally in an inert organic solvent at ambient to 139null C., wherein the reaction is carried out in the presence of a stereo isomer directing agent comprising an isomer of the compound of the formula I different from the desired isomer. The molar ratio of the stereoisomer directing agent to the dimethanol compound of the formula IV is a least 0.07. | ||||||
| 95 | Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors | US10112721 | 2002-04-02 | US20020161236A1 | 2002-10-31 | Michael E. Deason; Kathleen R. Whitten |
| HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates. | ||||||
| 96 | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors | US10101858 | 2002-03-21 | US06465661B1 | 2002-10-15 | Srinivasan Babu; Bennett C. Borer; Travis P. Remarchuk; Robert J. Szendroi; Kathleen R. Whitten; Juliette K. Busse; Kim F. Albizati |
| HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates. | ||||||
| 97 | Intermediates for making HIV-protease inhibitors | US923942 | 1997-09-05 | US6084107A | 2000-07-04 | Srinivasan Babu; Bennett C. Borer; Travis P. Remarchuk; Robert J. Szendroi; Kathleen R. Whitten; Juliette K. Busse; Kim F. Albizati |
| HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates. | ||||||
| 98 | Process for preparing diltiazem | US882387 | 1997-07-07 | US5869697A | 1999-02-09 | Lohray Braj Bhushan; Balakrishnan Ezhuthachan Jayachandran; Lohray Vidya Bhushan; Ravindranathan Thottappillil |
| A compound of formula (IV) ##STR1## wherein R.sup.1 is hydrogen, an alkyl, alkoxy, alkylamino, alkylthio, aryl, aryloxy, or halogen residue; R is an alkyl, or aryl residue, and X is S or C, which is a valuable intermediate for producing Diltiazem. | ||||||
| 99 | Chiral phospholanes via chiral 1,4-diol cyclic sulfates | US449861 | 1995-05-24 | US5532395A | 1996-07-02 | Mark J. Burk |
| This invention relates to novel chiral 1,4-diol cyclic sulfates and their use as precursors in the preparation of chiral phospholane ligands, and chiral complexes useful as catalysts for carrying out enantioselective reactions. | ||||||
| 100 | Cyclic oligomers for production of linear polyketones, polyphthalazines and polyisoquinolines | US367584 | 1995-01-03 | US5516566A | 1996-05-14 | Allan S. Hay; Kwok P. Chan |
| Low molecular weight cyclic oligomers of formula (I) ##STR1## in which n is an integer of 2 to 20, and each C in the oligomer is a radical of formula (II): ##STR2## and each X in the oligomer is --O--R--O-- or --S--R--S--, B and D are both carbonyl groups CO, or together represent a divalent radical of formula ##STR3## in which A.sub.1, A.sub.2, A.sub.3 A.sub.4, Ar.sub.1, Ar.sub.2 and Ar.sub.3 are selected from a variety of aromatic radicals, A.sub.1, A.sub.2, Ar.sub.3 and Ar.sub.4 also possibly being hydrogen, are useful in the production of high molecular weight, linear, polyketones, polyphthalazines and polyisoquinolines; the cyclic oligomers have low melt viscosities when heated above their softening temperatures and can be readily molded, whereafter they can be ring-open polymerized to form molded high molecular weight polymer products with excellent properties. | ||||||
QQ群二维码
意见反馈
意见反馈